Washington Research Foundation

Pacific Northwest Research Institute is a research institute for genetics and bioinformatics research.

Monod Bio is a life sciences company developing biosensors for detecting proteins, toxins, antibodies and other molecules. Its biosensor platform combines binding, transduction, and amplification in one step to detect a wide range of target molecules. The company leverages computational protein engineering to create modular bio-sensing nano switches that enable rapid, sensitive, and inexpensive analytical assays. Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.

SEngine Precision Medicine, Inc. is a Seattle-based company that specializes in personalized cancer treatment solutions. Founded in 2015, it operates a unique platform that utilizes functional genomics and robotic testing to analyze live patient organoids. This innovative approach allows the simultaneous testing of over 200 cancer drugs against an individual's tumor, providing insights into the most effective and least toxic treatment options that traditional DNA sequencing may not uncover. The company’s proprietary P.A.R.I.S assay empowers patients and oncologists with tailored treatment options, enhancing the decision-making process in oncology. Additionally, SEngine aggregates anonymized testing results to aid in the development of new cancer-targeted drugs, positioning itself at the forefront of precision medicine in oncology.

Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Phytelligence, Inc. is an agricultural biotechnology company that specializes in the cultivation and provision of disease-free plants and innovative solutions for growers, nurseries, and horticultural experts. Founded in 2012 and based in Pullman, Washington, the company offers a diverse range of tissue-cultured plantlets, including pear, apple, cherry, sweet cherry, grape, and strawberry. Phytelligence utilizes advanced propagation techniques and genetic analysis services to ensure the high quality and genetic integrity of its plants, enabling clients to achieve greater profitability through improved speed to harvest and reduced input costs. Its product portfolio also includes various series of rootstocks, such as the Geneva, Gisela, and Krymsk series, contributing to healthier and more resilient crops.

Founded in Seattle in 2008, Arzeda specializes in protein design technology. It creates and manufactures proteins and enzymes for pharmaceuticals, industrial chemicals, polymers, and other advanced applications.

WiBotic Inc. is a company specializing in wireless charging and power optimization solutions for robotic systems, including aerial, mobile, and underwater vehicles. Established in 2014 and headquartered in Seattle, Washington, WiBotic develops a range of products, including wireless charging systems, transmitters, onboard chargers, and antenna coils, as well as professional services. The company also offers advanced power management software that enhances battery performance and optimizes the operational efficiency of entire fleets of robots. This technology automatically detects when a robot or drone approaches a charging platform, facilitating seamless and autonomous battery charging. WiBotic's solutions are designed to be safe, reliable, and scalable, enabling clients to reduce charging and maintenance costs while maximizing battery lifespan and operational capabilities.

HyperSciences Inc., established in 2014 with headquarters in Spokane, Washington and an additional office in Austin, Texas, specializes in high-velocity drilling solutions for diverse applications such as tunneling, energy, transportation, aerospace, and materials production. The company's core product, HyperDrill, significantly enhances drilling speed by up to 10 times compared to conventional methods, catering primarily to the oil and gas, geothermal, construction, mining, and tunneling industries. HyperSciences' innovative technology employs low-cost chemical energy to accelerate consumable projectiles to hypersonic velocities, facilitating faster and deeper rock breaking and pulverization across varied conditions.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Nexgenia Inc., established in 2011 and based in Seattle, Washington, specializes in the development and manufacturing of proprietary polymer-based reagents for therapeutic and diagnostic applications. The company's core products are stimuli-responsive polymers and polymer-containing magnetic nanoparticles, which can change their state in response to minor environmental changes like temperature, pH, or salt concentration. These smart materials enable faster, more efficient molecular separations and immunoassays, benefiting diagnostic and life science applications by facilitating quicker results for physicians.

AnswerDash, Inc. is a technology company that specializes in providing contextual answer services for websites and mobile applications. Founded in 2012 and based in Seattle, Washington, AnswerDash offers a cloud-based platform that allows businesses to deliver self-service, point-and-click answers to users, thereby improving customer experience and reducing support costs. The platform integrates seamlessly with existing live chat services, enabling customers to seek personalized assistance when needed. By predicting user questions based on web page content and employing artificial intelligence, AnswerDash ensures that relevant information is readily available at the point of action. The company was previously known as Qazzow, Inc. until its name change in May 2014 and currently operates as a subsidiary of CloudEngage, Inc.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

FlexMinder, Inc. is a Seattle-based company that specializes in developing enterprise software solutions for private health exchanges, health carriers, and third-party administrators. Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, specifically for flexible spending accounts. The company's software aggregates healthcare information from various sources, streamlining the claims submission process for participants and significantly reducing manual processing time and costs for third-party administrators. By offering online tools that enhance the management of healthcare reimbursement accounts, FlexMinder aims to improve user experience and facilitate better financial management in the healthcare sector. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

AnswerDash, Inc. is a technology company that specializes in providing contextual answer services for websites and mobile applications. Founded in 2012 and based in Seattle, Washington, AnswerDash offers a cloud-based platform that allows businesses to deliver self-service, point-and-click answers to users, thereby improving customer experience and reducing support costs. The platform integrates seamlessly with existing live chat services, enabling customers to seek personalized assistance when needed. By predicting user questions based on web page content and employing artificial intelligence, AnswerDash ensures that relevant information is readily available at the point of action. The company was previously known as Qazzow, Inc. until its name change in May 2014 and currently operates as a subsidiary of CloudEngage, Inc.

FlexMinder, Inc. is a Seattle-based company that specializes in developing enterprise software solutions for private health exchanges, health carriers, and third-party administrators. Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, specifically for flexible spending accounts. The company's software aggregates healthcare information from various sources, streamlining the claims submission process for participants and significantly reducing manual processing time and costs for third-party administrators. By offering online tools that enhance the management of healthcare reimbursement accounts, FlexMinder aims to improve user experience and facilitate better financial management in the healthcare sector. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

Founded in Seattle in 2008, Arzeda specializes in protein design technology. It creates and manufactures proteins and enzymes for pharmaceuticals, industrial chemicals, polymers, and other advanced applications.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

HaloSource Corporation is a clean water technology company that focuses on developing and manufacturing innovative drinking water treatment solutions for global markets. Established in 2017 and headquartered in Bothell, Washington, the company leverages proprietary polymer chemistries to create a range of products aimed at improving water quality. Its offerings include gravity-based devices like the HaloPure disinfecting pitchers and associated cartridges, as well as pressurized devices such as bacteriostatic water cartridges and ceramic candle inserts. The HaloPure technology is recognized for its high international certifications, including registration with the US EPA, and serves over 10 million consumers worldwide. Additionally, HaloSource is expanding its product line to include lead removal media and is actively engaged in partnerships with trusted brands to further enhance its market presence. The company is well-positioned to capitalize on opportunities in the residential water treatment sector, supported by a robust pipeline of new products and strong regulatory compliance.

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

In the spring of 2002, Vanson, Inc. and HaloSource Corp. merged to form Vanson HaloSource, Inc. in order to expand opportunities for product commercialization by capitalizing on manufacturing facilities, distribution channels and intellectual property. Vanson’s cGMP certified manufacturing facility, located in Western Washington accommodates the production of most of Vanson HaloSource's products. The management team and a talented pool of chemists, biochemists and microbiologists are working together to create and expand the Company’s broad spectrum of applications. Today the Company holds dozens of patents and patents pending on a broad range of products that are distributed to the pool and spa, wastewater treatment, and biomedical industries. The Company has a substantial pipeline of proprietary new products in research and development, and a growing number of strategic alliances with prestigious companies to manufacture and market value-added chitin/chitosan-based and antimicrobial products.